Articles published by Axcella Therapeutics

Axcella Announces Reverse Stock Split Effective September 19, 2023

September 14, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Granted Patent for Long COVID Fatigue Treatment

August 29, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Reports Second Quarter Financial Results and Provides Business Update

August 03, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Reports First Quarter Financial Results and Provides Business Update

May 04, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023

April 17, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 30, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

February 15, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference

February 09, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

January 23, 2023

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Announces Program Reprioritization and Corporate Restructuring

December 14, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

November 03, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Reports Third Quarter Financial Results and Provides Business Update

November 01, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022

October 27, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

October 14, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members

October 13, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)

September 29, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

September 12, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Reports Second Quarter Financial Results and Provides Business Update

August 12, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

August 02, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

May 26, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

May 19, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Reports First Quarter Financial Results and Provides Business Update

May 05, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 30, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022

March 23, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market

March 16, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

February 14, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

February 10, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics Announces Appointment of New Chief Financial Officer

February 07, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics Details Clinical and Operational Milestones for 2022

January 06, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference

January 04, 2022

From Axcella Therapeutics

Via Business Wire

Tickers AXLA

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.